EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Microbiome and Metabolome Restoration After Administration of Fecal Microbiota, Live-jslm (REBYOTA) for Preventing Recurrent Clostridioides difficile Infection

Ken F Blount, Romeo Papazyan, Nicky Ferdyan, Karthik Srinivasan, Carlos Gonzalez, William D Shannon, Bryan C Fuchs

The Journal of Infectious Diseases · 11.07.2025 · 231 (6) · e1022-e1033

DOI: 10.1093/infdis/jiae418 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 22.08.2024. Verfasst von Ken F Blount und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ferring Pharmaceuticals, Roseville, Minnesota. Hauptthemen laut MEDLINE: Clostridium Infections, Metabolome, Feces, Fecal Microbiota Transplantation. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Rebiotix, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Microbiota-based treatments are effective in preventing recurrent Clostridioides difficile infection. Fecal microbiota, live-jslm (REBYOTA; RBL, previously RBX2660) was shown to prevent recurrent C difficile infection in a phase 3 clinical trial (PUNCH CD3) based on a randomized, double-blinded, placebo-controlled design.

Methods

Stool samples from participants in PUNCH CD3 who received a single blinded dose of rectally administered RBL or placebo were sequenced to determine microbial community composition and calculate the Microbiome Health Index for postantibiotic dysbiosis. The composition of bile acids (BAs) in the same samples was quantified by liquid chromatography–mass spectrometry. Relationships between BA composition and microbiota community structure and correlations with treatment outcomes were assessed.

Results

Before administration, Gammaproteobacteria and Bacilli dominated the microbiota community, and primary BAs were more prevalent than secondary BAs. Clinical success after administration correlated with shifts to predominantly Bacteroidia and Clostridia, a significant increase in Microbiome Health Index for postantibiotic dysbiosis, and a shift from primary to secondary BAs. Several microbiota and BA changes were more extensive in RBL-treated responders as compared with placebo-treated responders, and microbiota changes correlated with BA changes.

Conclusions

Clinical response and RBL administration were associated with significant restoration of microbiota and BA composition. Clinical Trials Registration NCT03244644 (https://clinicaltrials.gov/ct2/show/NCT03244644).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clostridium InfectionsMetabolomeFecesFecal Microbiota TransplantationGastrointestinal MicrobiomeProbioticsHumansMaleFemaleDouble-Blind MethodClostridioides difficileMiddle AgedAdultBile Acids and SaltsAgedDysbiosisTreatment Outcome

Stichwörter der Autor:innen

Clostridioides difficile infectionclinical trialsmetabolomemicrobiota-based therapyrecurrence

Substanzen

Bile Acids and Salts

Autor:innen und Institutionen

  • Ferring Pharmaceuticals, Roseville, Minnesota.
  • Ferring Research Institute, San Diego, California.
  • BioRankings, St Louis, Missouri.
  • John T. Milliken Department of Medicine, Washington University in St Louis, Missouri.

Förderung

  • Rebiotix, Inc

Zitieren

APA

Blount, K. F., Papazyan, R., Ferdyan, N., Srinivasan, K., Gonzalez, C., Shannon, W. D., & Fuchs, B. C. (2025). Microbiome and Metabolome Restoration After Administration of Fecal Microbiota, Live-jslm (REBYOTA) for Preventing Recurrent Clostridioides difficile Infection. The Journal of Infectious Diseases, 231(6), e1022-e1033. https://doi.org/10.1093/infdis/jiae418

Vancouver

Blount KF, Papazyan R, Ferdyan N, Srinivasan K, Gonzalez C, Shannon WD, et al. Microbiome and Metabolome Restoration After Administration of Fecal Microbiota, Live-jslm (REBYOTA) for Preventing Recurrent Clostridioides difficile Infection. The Journal of Infectious Diseases. 2025;231(6):e1022-e1033. doi:10.1093/infdis/jiae418

BibTeX
@article{Blount2025,
  author = {Blount, Ken F and Papazyan, Romeo and Ferdyan, Nicky and Srinivasan, Karthik and Gonzalez, Carlos and Shannon, William D and Fuchs, Bryan C},
  title = {Microbiome and Metabolome Restoration After Administration of Fecal Microbiota, Live-jslm (REBYOTA) for Preventing Recurrent Clostridioides difficile Infection},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  volume = {231},
  number = {6},
  pages = {e1022--e1033},
  doi = {10.1093/infdis/jiae418}
}
Kostenlos starten →